Andrew von Eschenbach

Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC.

HistoSonics, Inc. develops medical devices. The company was founded by Christine Gibbons, Jim Bertolina, Zhen Xu, William Robert, Hall Timothy, J. Brian Fowlkes, Thomas W. Davison, and Charles Cain in November 2009 and is headquartered in Ann Arbor, MI.

Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC.

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. The company was founded on September 24, 2012 and is headquartered in Fremont, CA.

Innocrin Pharmaceuticals Holdings LLC discovers and develops oral inhibitors for the treatment of Castration-Resistant Prostate Cancer (CRPC). The company is headquartered in Durham, NC.

National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD.

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

The University of Texas M.D. Anderson Cancer Center provides cancer patient care, research, and prevention for cancer. The firm also provides education for undergraduate and graduate students, trainees, professionals, employees and the publics. The company was founded in 1941 and is headquartered in Houston, TX.

US Food & Drug Administration operates agencies to protect health and human services. It protects and promotes public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, cosmetics, animal foods and feed and veterinary products. The company was founded by Theodore Roosevelt and Harvey Washington Wiley on 30th June, 1906 and is headquartered in Silver Spring, MD.

Banyan Biomarkers, Inc. engages in the commercialization of vitro diagnostic tests for the detection of brain injury and neurological diseases. It develops blood test to accurately and quickly diagnose traumatic brain injury. The company was founded by Nancy Denslow, Ronald L. Hayes, and Kevin Wang in 2002 and is headquartered in San Diego, CA.

National Comprehensive Cancer Network, Inc. provides research and development services to fight against cancer. The organization develops resources that present information to the numerous stakeholders in the health care delivery system. The company was founded in 1995 and is headquartered in Fort Washington, PA.

Manhattan Institute For Policy Research, Inc. develops and disseminate new ideas for greater economic choice and individual responsibility. It focuses on economic growth, education, energy and environment, health care, legal reform, public sector, race and urban policy. The company was founded by Antony Fisher and William J. Casey in 1977 and is headquartered in New York, NY.

Focused Ultrasound Foundation is an early-sage company, which engages in the provision of non-invasive therapeutic technology. It focuses on cardiovascular, endocrine disorders, gastrointestinal, musculoskeletal, neurological, oncological, urological, and women''s health sectors. The company was founded by Neal F. Kassell and is headquartered in Charlottesville, VA.

Cypher Genomics, Inc. provides automated human genome interpretation software solutions. It offers molecular diagnostics, drug development, and science and technology. The company was founded by Ashley Van Zeeland and Ali Torkamani in 2011 and is headquartered in San Diego, CA.

Wavebreak Therapeutics Ltd. operates as a biopharmaceutical company that focuses on drug discovery and subsequent clinical translation of molecules which will impact protein misfolding diseases. Its proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. The company was founded by Christopher Dobson, Michele Vendruscolo, and Tuomas Knowles on March 10, 2016 and is headquartered in Cambridge, the United Kingdom.

Celularity, Inc. engages in biotechnology company. The firm focuses on the study of placenta. The company was founded in Robert Joseph Hariri Gordon and Peter H. Diamandis in 2016 and is headquartered in Florham Park, NJ.

Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC.